721880-65-5

Basic information

• Product Name: C₁₀H₁₂BrNO₂
• CAS NO: 721880-65-5
• Molecular Weight: 258.115
• Mol File: 721880-65-5.mol

Chemical Properties

• CAS DataBase Reference: C₁₀H₁₂BrNO₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₀H₁₂BrNO₂(721880-65-5)
• EPA Substance Registry System: C₁₀H₁₂BrNO₂(721880-65-5)

Safety Data

• Hazardous Substances Data: 721880-65-5(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 
• 546115-43-9 methyl (S)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 30163-20-3 2-amino-3-(3-bromophenyl)propanoic acid 
• 267225-27-4 (2R)-2-amino-3-(2-bromophenyl)propanoic acid 

Relevant articles and documents

CHEMICAL COMPOUNDS

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.

LXR INVERSE AGONISTS FOR TREATMENT OF CANCER

In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.

Design of selective Cathepsin inhibitors

A number of molecular recognition features have been exploited in structure-based design of selective Cathepsin inhibitors.

SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS

Disclosed are novel compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4 and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula (I) and at least one compound selected from the group consisting of β-secretase inhibitors other than those of formula (I), HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.